Quantcast

Latest Sunitinib Stories

2014-08-12 08:30:30

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Hirth is an industry leader and innovator with over 30 years of biotechnology and pharmaceutical discovery and development experience. A pioneer in the field of personalized medicine, Dr. Hirth led the organizations that developed both Sutent(®) and Zelboraf(®);...

2014-08-11 12:26:57

Significant Opportunity Exists for New Therapies to Treat GIST, Particularly those for Treating Unresectable and/or Metastatic Disease in Later-Line Settings BURLINGTON, Mass., Aug. 11, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through 2023 as no new therapies are expected to launch for this indication. Treatment of GIST is largely dependent on tumor size, location and growth rate and...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-05-31 08:21:17

Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that data from the PROCLAIM(SM) national patient registry retrospective cohort document an improvement in median overall survival (OS) in patients with metastatic melanoma who were treated with high-dose Proleukin(®) (aldesleukin) as compared to...

2014-05-14 16:29:06

WHIPPANY, N.J., May 14, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including NEXAVAR(®) (sorafenib) tablets, Xofigo(®) (radium Ra 223 dichloride) injection and Stivarga(®) (regorafenib) tablets, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago, IL (USA). Bayer will also present data from its late stage clinical pipeline, investigating...

2014-05-06 16:29:13

LONDON, May 6, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapieshttp://www.reportbuyer.com/pharma_healthcare/diseases/solid_tumors_market_asia_pacific_2019_new_drug_approvals_anticipated_product_launches_trigger_shift_treatment_paradigm_targeted_therapies.htmlSolid Tumors Market in Asia Pacific to...

2014-04-22 12:31:30

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/gastrointestinal_stromal_tumor_gist_global_clinical_trials_review.html Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Gastrointestinal Stromal Tumor (GIST) Global...

2014-02-20 04:21:29

WHIPPANY, N.J., Feb. 20, 2014 /PRNewswire/ -- Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga(®) (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases. The randomized, double-blind, placebo-controlled Phase III trial is designed to determine the effects of Stivarga as adjuvant treatment following surgical removal of liver metastases.(1) "Patients with more advanced colorectal cancer often...

2013-12-05 23:23:04

A recent study featured in the latest issue of The Oncologist shows that active smoking greatly diminishes patients’ chances of responding to chemotherapeutic treatment for renal cell carcinoma (RCC). The research team, jointly led by Dr. Michael Carducci from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD and Dr. Daniel Keizman from the Sackler School of Medicine at Tel Aviv University, conducted a retrospective analysis exploring the association of...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related